SCCS Publishes Opinions on Cannabidiol, Acetophenone and Heliotropin
Heliotropin (CAS No. 120-57-0, EC No. 204-409-7)
On 15 April 2026, based on the assessment of data provided and taking into consideration the concerns related to the possible classification as ‘Repr.1B’ under Regulation (EC) No 1272/2008 (CLP Regulation), the SCCS considers Heliotropin safe when used up to the maximum concentration of 1.8% only in fine fragrances for adults.
Cannabidiol (CBD) (CAS/EC No. 13956-29- 1/ 689-176-3)
The SCCS opinion, published on 24 April 2026, assesses the maximum safe concentration of Cannabidiol in cosmetic products.
The SCCS concluded that a concentration of up to 0.19% is safe for dermal and oral cosmetic products, whether used separately or together.
THC impurities are considered safe in dermal or oral cosmetics at levels up to 0.00025%.
This Scientific Advice excludes CBD use in cosmetic products that could expose the end user’s lungs through inhalation.
Acetophenone (CAS No. 98-86-2, EC No. 202-708-7)
On 4 May 2026, in light of the data provided and taking into consideration the possible classification as ‘Repr.1B’ under Regulation (EC) No 1272/2008 (CLP Regulation), SCCS published a draft opinion concluding that Acetophenone is safe in cosmetic products at concentrations up to 100 ppm (0.01%). This assessment accounts for exposure from other sources, including food and tobacco smoke.
Need help navigating these changes?
Reach out to our regulatory experts for tailored guidance and support in adapting to the new requirements.
Subscribe to our newsletter to stay informed on future amendments and industry insights.